Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.61 USD | -2.03% | +1.82% | +0.12% |
May. 29 | Haemonetics Insider Sold Shares Worth $1,144,208, According to a Recent SEC Filing | MT |
May. 29 | Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With a 2025 P/E ratio at 28.51 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.12% | 4.36B | B- | ||
-2.26% | 187B | C+ | ||
+2.05% | 110B | C | ||
-1.31% | 69.54B | A | ||
+14.65% | 46.37B | B- | ||
-6.69% | 46.05B | B- | ||
+7.97% | 42.54B | B+ | ||
+18.60% | 30.72B | B | ||
+17.70% | 25.62B | A- | ||
-6.87% | 23.32B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HAE Stock
- Ratings Haemonetics Corporation